カテゴリ： 世界, 医療/バイオ, Market Monitor Global

経口用JAK1阻害剤のグローバル市場展望 2023年-2029年：ブランド、バイオシミラー

■ 英語タイトル：Oral JAK1 Inhibitor Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC16507）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC16507
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品
■ ページ数：61
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[経口用JAK1阻害剤のグローバル市場展望 2023年-2029年：ブランド、バイオシミラー]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の経口用JAK1阻害剤市場規模と予測を収録しています。・世界の経口用JAK1阻害剤市場：売上、2018年-2023年、2024年-2029年
・世界の経口用JAK1阻害剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の経口用JAK1阻害剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ブランド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

経口用JAK1阻害剤のグローバル主要企業は、AbbVie、 Pfizer、 Incyte、 Eli Lilly、 Bristol-Myers Squibbなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、経口用JAK1阻害剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の経口用JAK1阻害剤市場：タイプ別、2018年-2023年、2024年-2029年
世界の経口用JAK1阻害剤市場：タイプ別市場シェア、2022年
・ブランド、バイオシミラー

世界の経口用JAK1阻害剤市場：用途別、2018年-2023年、2024年-2029年
世界の経口用JAK1阻害剤市場：用途別市場シェア、2022年
・病院、小売薬局、その他

世界の経口用JAK1阻害剤市場：地域・国別、2018年-2023年、2024年-2029年
世界の経口用JAK1阻害剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における経口用JAK1阻害剤のグローバル売上、2018年-2023年
・主要企業における経口用JAK1阻害剤のグローバル売上シェア、2022年
・主要企業における経口用JAK1阻害剤のグローバル販売量、2018年-2023年
・主要企業における経口用JAK1阻害剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
AbbVie、 Pfizer、 Incyte、 Eli Lilly、 Bristol-Myers Squibb

*************************************************************

・調査・分析レポートの概要
経口用JAK1阻害剤市場の定義
市場セグメント
世界の経口用JAK1阻害剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の経口用JAK1阻害剤市場規模
世界の経口用JAK1阻害剤市場規模：2022年 VS 2029年
世界の経口用JAK1阻害剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの経口用JAK1阻害剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の経口用JAK1阻害剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ブランド、バイオシミラー
経口用JAK1阻害剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、小売薬局、その他
経口用JAK1阻害剤の用途別グローバル売上・予測

・地域別市場分析
地域別経口用JAK1阻害剤市場規模 2022年と2029年
地域別経口用JAK1阻害剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
AbbVie、 Pfizer、 Incyte、 Eli Lilly、 Bristol-Myers Squibb
...

This research report provides a comprehensive analysis of the Oral JAK1 Inhibitor market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Oral JAK1 Inhibitor market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Oral JAK1 Inhibitor, challenges faced by the industry, and potential opportunities for market players.
The global Oral JAK1 Inhibitor market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Oral JAK1 Inhibitor market presents opportunities for various stakeholders, including Hospita, Retail Pharmacy. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Oral JAK1 Inhibitor market. Additionally, the growing consumer demand present avenues for market expansion.
The global Oral JAK1 Inhibitor market was valued at US$ 7693.5 million in 2022 and is projected to reach US$ 13110 million by 2029, at a CAGR of 7.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Oral JAK1 Inhibitor market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Oral JAK1 Inhibitor market.
Market Overview: The report provides a comprehensive overview of the Oral JAK1 Inhibitor market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Brands, Biosimilar), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Oral JAK1 Inhibitor market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Oral JAK1 Inhibitor market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Oral JAK1 Inhibitor market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Oral JAK1 Inhibitor market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Oral JAK1 Inhibitor market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Oral JAK1 Inhibitor market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Oral JAK1 Inhibitor, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Oral JAK1 Inhibitor market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Oral JAK1 Inhibitor market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Brands
Biosimilar
Market segment by Application
Hospita
Retail Pharmacy
Other
Global Oral JAK1 Inhibitor Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
AbbVie
Pfizer
Incyte
Eli Lilly
Bristol-Myers Squibb
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oral JAK1 Inhibitor, market overview.
Chapter 2: Global Oral JAK1 Inhibitor market size in revenue.
Chapter 3: Detailed analysis of Oral JAK1 Inhibitor company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oral JAK1 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Oral JAK1 Inhibitor Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oral JAK1 Inhibitor Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oral JAK1 Inhibitor Overall Market Size
2.1 Global Oral JAK1 Inhibitor Market Size: 2022 VS 2029
2.2 Global Oral JAK1 Inhibitor Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oral JAK1 Inhibitor Players in Global Market
3.2 Top Global Oral JAK1 Inhibitor Companies Ranked by Revenue
3.3 Global Oral JAK1 Inhibitor Revenue by Companies
3.4 Top 3 and Top 5 Oral JAK1 Inhibitor Companies in Global Market, by Revenue in 2022
3.5 Global Companies Oral JAK1 Inhibitor Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oral JAK1 Inhibitor Players in Global Market
3.6.1 List of Global Tier 1 Oral JAK1 Inhibitor Companies
3.6.2 List of Global Tier 2 and Tier 3 Oral JAK1 Inhibitor Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Oral JAK1 Inhibitor Market Size Markets, 2022 & 2029
4.1.2 Brands
4.1.3 Biosimilar
4.2 By Type – Global Oral JAK1 Inhibitor Revenue & Forecasts
4.2.1 By Type – Global Oral JAK1 Inhibitor Revenue, 2018-2023
4.2.2 By Type – Global Oral JAK1 Inhibitor Revenue, 2024-2029
4.2.3 By Type – Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Oral JAK1 Inhibitor Market Size, 2022 & 2029
5.1.2 Hospita
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Oral JAK1 Inhibitor Revenue & Forecasts
5.2.1 By Application – Global Oral JAK1 Inhibitor Revenue, 2018-2023
5.2.2 By Application – Global Oral JAK1 Inhibitor Revenue, 2024-2029
5.2.3 By Application – Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Oral JAK1 Inhibitor Market Size, 2022 & 2029
6.2 By Region – Global Oral JAK1 Inhibitor Revenue & Forecasts
6.2.1 By Region – Global Oral JAK1 Inhibitor Revenue, 2018-2023
6.2.2 By Region – Global Oral JAK1 Inhibitor Revenue, 2024-2029
6.2.3 By Region – Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Oral JAK1 Inhibitor Revenue, 2018-2029
6.3.2 US Oral JAK1 Inhibitor Market Size, 2018-2029
6.3.3 Canada Oral JAK1 Inhibitor Market Size, 2018-2029
6.3.4 Mexico Oral JAK1 Inhibitor Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Oral JAK1 Inhibitor Revenue, 2018-2029
6.4.2 Germany Oral JAK1 Inhibitor Market Size, 2018-2029
6.4.3 France Oral JAK1 Inhibitor Market Size, 2018-2029
6.4.4 U.K. Oral JAK1 Inhibitor Market Size, 2018-2029
6.4.5 Italy Oral JAK1 Inhibitor Market Size, 2018-2029
6.4.6 Russia Oral JAK1 Inhibitor Market Size, 2018-2029
6.4.7 Nordic Countries Oral JAK1 Inhibitor Market Size, 2018-2029
6.4.8 Benelux Oral JAK1 Inhibitor Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Oral JAK1 Inhibitor Revenue, 2018-2029
6.5.2 China Oral JAK1 Inhibitor Market Size, 2018-2029
6.5.3 Japan Oral JAK1 Inhibitor Market Size, 2018-2029
6.5.4 South Korea Oral JAK1 Inhibitor Market Size, 2018-2029
6.5.5 Southeast Asia Oral JAK1 Inhibitor Market Size, 2018-2029
6.5.6 India Oral JAK1 Inhibitor Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Oral JAK1 Inhibitor Revenue, 2018-2029
6.6.2 Brazil Oral JAK1 Inhibitor Market Size, 2018-2029
6.6.3 Argentina Oral JAK1 Inhibitor Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Oral JAK1 Inhibitor Revenue, 2018-2029
6.7.2 Turkey Oral JAK1 Inhibitor Market Size, 2018-2029
6.7.3 Israel Oral JAK1 Inhibitor Market Size, 2018-2029
6.7.4 Saudi Arabia Oral JAK1 Inhibitor Market Size, 2018-2029
6.7.5 UAE Oral JAK1 Inhibitor Market Size, 2018-2029
7 Oral JAK1 Inhibitor Companies Profiles
7.1 AbbVie
7.1.1 AbbVie Company Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Oral JAK1 Inhibitor Major Product Offerings
7.1.4 AbbVie Oral JAK1 Inhibitor Revenue in Global Market (2018-2023)
7.1.5 AbbVie Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Oral JAK1 Inhibitor Major Product Offerings
7.2.4 Pfizer Oral JAK1 Inhibitor Revenue in Global Market (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Incyte
7.3.1 Incyte Company Summary
7.3.2 Incyte Business Overview
7.3.3 Incyte Oral JAK1 Inhibitor Major Product Offerings
7.3.4 Incyte Oral JAK1 Inhibitor Revenue in Global Market (2018-2023)
7.3.5 Incyte Key News & Latest Developments
7.4 Eli Lilly
7.4.1 Eli Lilly Company Summary
7.4.2 Eli Lilly Business Overview
7.4.3 Eli Lilly Oral JAK1 Inhibitor Major Product Offerings
7.4.4 Eli Lilly Oral JAK1 Inhibitor Revenue in Global Market (2018-2023)
7.4.5 Eli Lilly Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Oral JAK1 Inhibitor Major Product Offerings
7.5.4 Bristol-Myers Squibb Oral JAK1 Inhibitor Revenue in Global Market (2018-2023)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Oral JAK1 Inhibitor Market Opportunities & Trends in Global Market
Table 2. Oral JAK1 Inhibitor Market Drivers in Global Market
Table 3. Oral JAK1 Inhibitor Market Restraints in Global Market
Table 4. Key Players of Oral JAK1 Inhibitor in Global Market
Table 5. Top Oral JAK1 Inhibitor Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Oral JAK1 Inhibitor Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Oral JAK1 Inhibitor Revenue Share by Companies, 2018-2023
Table 8. Global Companies Oral JAK1 Inhibitor Product Type
Table 9. List of Global Tier 1 Oral JAK1 Inhibitor Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oral JAK1 Inhibitor Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Oral JAK1 Inhibitor Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Oral JAK1 Inhibitor Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Oral JAK1 Inhibitor Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Oral JAK1 Inhibitor Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Oral JAK1 Inhibitor Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Oral JAK1 Inhibitor Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Oral JAK1 Inhibitor Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Oral JAK1 Inhibitor Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Oral JAK1 Inhibitor Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Oral JAK1 Inhibitor Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Oral JAK1 Inhibitor Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Oral JAK1 Inhibitor Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Oral JAK1 Inhibitor Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Oral JAK1 Inhibitor Revenue, (US$, Mn), 2024-2029
Table 30. AbbVie Company Summary
Table 31. AbbVie Oral JAK1 Inhibitor Product Offerings
Table 32. AbbVie Oral JAK1 Inhibitor Revenue (US$, Mn) & (2018-2023)
Table 33. AbbVie Key News & Latest Developments
Table 34. Pfizer Company Summary
Table 35. Pfizer Oral JAK1 Inhibitor Product Offerings
Table 36. Pfizer Oral JAK1 Inhibitor Revenue (US$, Mn) & (2018-2023)
Table 37. Pfizer Key News & Latest Developments
Table 38. Incyte Company Summary
Table 39. Incyte Oral JAK1 Inhibitor Product Offerings
Table 40. Incyte Oral JAK1 Inhibitor Revenue (US$, Mn) & (2018-2023)
Table 41. Incyte Key News & Latest Developments
Table 42. Eli Lilly Company Summary
Table 43. Eli Lilly Oral JAK1 Inhibitor Product Offerings
Table 44. Eli Lilly Oral JAK1 Inhibitor Revenue (US$, Mn) & (2018-2023)
Table 45. Eli Lilly Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company Summary
Table 47. Bristol-Myers Squibb Oral JAK1 Inhibitor Product Offerings
Table 48. Bristol-Myers Squibb Oral JAK1 Inhibitor Revenue (US$, Mn) & (2018-2023)
Table 49. Bristol-Myers Squibb Key News & Latest Developments
List of Figures
Figure 1. Oral JAK1 Inhibitor Segment by Type in 2022
Figure 2. Oral JAK1 Inhibitor Segment by Application in 2022
Figure 3. Global Oral JAK1 Inhibitor Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oral JAK1 Inhibitor Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Oral JAK1 Inhibitor Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Oral JAK1 Inhibitor Revenue in 2022
Figure 8. By Type - Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 9. By Application - Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 10. By Type - Global Oral JAK1 Inhibitor Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 12. By Application - Global Oral JAK1 Inhibitor Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 14. By Region - Global Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 15. By Country - North America Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 16. US Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 20. Germany Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 21. France Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 28. China Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 32. India Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 34. Brazil Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Oral JAK1 Inhibitor Revenue Market Share, 2018-2029
Figure 37. Turkey Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Oral JAK1 Inhibitor Revenue, (US$, Mn), 2018-2029
Figure 41. AbbVie Oral JAK1 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Pfizer Oral JAK1 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Incyte Oral JAK1 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Eli Lilly Oral JAK1 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bristol-Myers Squibb Oral JAK1 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 口腔用粘膜ドラッグデリバリーシステムのグローバル市場展望 2023年-2029年：舌下ドラッグデリバリーシステム、口腔粘膜ドラッグデリバリーシステム、歯肉粘膜ドラッグデリバリーシステム
  • ゲパンツドラッグのグローバル市場展望 2023年-2029年：リメゲパン、アトゲパン、ザベゲパン、ウブロゲパン
  • 自己免疫疾患におけるキナーゼ阻害剤の世界市場2023年：理学療法、外科、その他
  • 閉経後骨粗鬆症治療のグローバル市場展望 2023年-2029年：ビスホスホネート、ビタミンD3、エストロゲンアゴニスト/アンタゴニスト、ホルモン補充療法、副甲状腺ホルモン療法、その他
  • Rho関連プロテインキナーゼ1のグローバル市場展望 2023年-2029年：AN-3485、KL-01045、AT-13148、TRX-101、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC16507 )"経口用JAK1阻害剤のグローバル市場展望 2023年-2029年：ブランド、バイオシミラー" (英文：Oral JAK1 Inhibitor Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。